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TGF-βEpithelial–mesenchymal transition (EMT) of tubular cells is one of themechanisms which contribute to renal ﬁ-
brosis and transforming growth factor-β (TGF-β) is one of themain triggers. Heparanase (HPSE) is an endo-β-D-
glucuronidase that cleaves heparan-sulfate thus regulating the bioavailability of growth factors (FGF-2, TGF-β).
HPSE controls FGF-2-induced EMT in tubular cells and is necessary for the development of diabetic nephropathy
in mice.
The aim of this study was to investigate whether HPSE can modulate the expression and the effects of TGF-β in
tubular cells.
First we proved that the lack of HPSE or its inhibition prevents the increased synthesis of TGF-β by tubular cells in
response to pro-ﬁbrotic stimuli such as FGF-2, advanced glycosylation end products (AGE) and albumin overload.
Second, since TGF-βmay derive from sources different from tubular cells, we investigated whether HPSEmodu-
lates tubular cell response to exogenous TGF-β. HPSE does not prevent EMT induced by TGF-β although it slows
its onset; indeed in HPSE-silenced cells the acquisition of a mesenchymal phenotype does not develop as quickly
as inwt cells. Additionally, TGF-β induces an autocrine loop to sustain its signal, whereas the lack of HPSE partial-
ly interferes with this autocrine loop.
Overall these data conﬁrm that HPSE is a key player in renal ﬁbrosis since it interacts with the regulation and the
effects of TGF-β. HPSE is needed for pathological TGF-β overexpression in response to pro-ﬁbrotic factors. Fur-
thermore, HPSEmodulates TGF-β-induced EMT: the lack of HPSE delays tubular cell transdifferentiation, and im-
pairs the TGF-β autocrine loop.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Multiple-drug therapy has led, over the years, to a signiﬁcant
slowing of chronic kidney disease progression towards end-stage
renal disease, but we are still far from the development of therapeutic
interventions able to stop this process. Clinical-pathological studies
have clearly shown that ﬁbrosis is the common, ﬁnal event of a broad
range of kidney diseases whatever their etiology. In the progression to-
ward end-stage renal disease (ESRD), the majority of pathogenicoducts; α-SMA, alpha-smooth
,ﬁbronectin; HPSE, heparanase;
wth factor-β; VIM, vimentin




nisto@unipd.it (M. Onisto).mechanisms underlying renal ﬁbrosis arise in the tubular compartment
[1]. Actually, several chronic kidney diseases are characterized by pro-
gressive tubule-interstitial ﬁbrosis as evidenced by accumulation of ﬁ-
broblasts and increase of interstitial matrix [2]. This leads to organ
failure and thus dialysis or organ transplantation is required [1]
Among the causes of chronic renal failure, diabetic nephropathy is one
of the most common in developed countries [3]. Damage to the renal
tissues caused by diabetes is due to the high concentration of glucose,
the products of advanced glycation and proteinuria.
A key role in tubulo-interstitial ﬁbrosis is the tubular epithelial-to-
mesenchymal transition (EMT), or transdifferentiation of tubular epi-
thelial cells into myoﬁbroblasts, [4] which are the cells responsible for
the secretion and accumulation of extracellular matrix components:
collagens, ﬁbronectin (FN) and laminin [5].
The EMT implies the loss of epithelialmarkers, such as epithelial (E)-
cadherin and zona occludence-1, and the expression of proteins and bi-
ological features associated with a mesenchymal phenotype. Epithelial
cells in transition become mobile, and vimentin (VIM) and alpha-
smoothmuscle actin (α-SMA) are up-regulated. Following cytoskeleton
2123V. Masola et al. / Biochimica et Biophysica Acta 1843 (2014) 2122–2128remodeling, release of matrix metalloproteinases (MMPs) and tubular
basement membrane disruption, cells with an acquired myoﬁbroblasts
proﬁle develop the ability to migrate into the interstitium [6].
In chronic kidney disease, different stresses such as proteinuria, high
glucose, advanced glycosylation end products (AGE) or hypoxia induce
tubular epithelial cells to release cytokines and chemokines. These mol-
ecules recruit macrophages and circulating lymphocytes which trigger
an immune response and the release of others mediators such as
transforming growth factor-β (TGF-β), epidermal growth factor and ﬁ-
broblast growth factor-2 (FGF-2) [7]. All these growth factors elicit EMT
in tubular cells [8–10]. In diabetic nephropathy (DN), glycated (AGE)
and naïve proteins ﬁltered through damaged glomeruli are also able
to induce EMT of proximal tubular cells [11,12].
HPSE is an endo-β-D-glucuronidase that cleaves the beta-(1,4)-gly-
cosidic bond between glucuronic acid and glucosamine residues in hep-
aran sulfate (HS) chains; it is expressed by several cell types and tissues
where it participates in ECM remodeling and degradation, and in the
regulation of the release of HS-bonded molecules from ECM storages,
such as growth factors, chemokines, cytokines, and enzymes involved
in inﬂammation, wound healing and tumor invasion [13]. Evidence
from previous literature supports the hypothesis that HPSE, which is
overexpressed by glomerular and tubular cells in diabetes, is involved
in the pathogenesis of renal proteinuric disorders [14,15].
In tubular cells, HPSE is a target gene of the DN mediators, albumin
and advanced glycation end-product (AGE)[16] and experimental ﬁnd-
ings show that a relationship exists betweenHPSE and FGF-2 [15–18]. In
particular, we have previously demonstrated that HPSE regulates
syndecan-1, a transmembrane HS proteoglycan that controls FGF-2 sig-
naling [19]. Moreover, we have provided evidence that HPSE is speciﬁ-
cally involved in the establishment of tubular ﬁbrosis being necessary
for the FGF-2 induced EMT of tubular cells [20]. Furthermore, FGF-2 in-
duces an HPSE-dependent autocrine loop to sustain its signal [20],
which is inhibited by heparins [21]. Interestingly, heparins favorably af-
fect the development and progression of DN [22] and are efﬁcient HPSE
inhibitors [23].
That HPSE plays a crucial role in the pathogenesis of DN is highlight-
ed by the importance of HPSE in the development of DN in a
streptozotocin-induced diabetes model, where the HPSE gene-KO pro-
tects mice from developing DN. In particular, HPSE-KOmice did not de-
velop proteinuria, mesangial matrix expansion, and tubulo-interstitial
ﬁbrosis. Conﬁrming such a role, the inhibition of HPSE in wt mice by a
speciﬁc inhibitor resulted in decrease of proteinuria [24]. Notably, in di-
abetic HPSE-KO-mice renal TGF-β, the most pro-ﬁbrotic growth factor
in the kidneywhich is considered to play a pivotal role in the pathogen-
esis of DN did not increase at odds with naïve diabetic animals.
In view of the role of EMT in tubular cells and TGF-β in the progres-
sive accumulation of extracellular matrix in renal ﬁbrosis, and the criti-
cal role of HPSE in EMT [20] and TGF-β expression [24] we have
investigated whether TGF-β, similarly to FGF-2 [20] has a role in the
HPSE-mediated control of EMT.
2. Methods
2.1. Cell cultures and treatments
Two different cell lines were used: 1) HK2 (human kidney 2), a
human renal proximal tubular cell line; and 2) a stably HPSE-silenced
HK2 cell line obtained by transfection with shRNA plasmid targeting
human HPSE as recently described elsewhere [19].
Both cell lines were grown in DMEM-F12 (EuroClone) (17.5 mM
glucose) supplemented with 10% fetal bovine serum (Biochrom
AG), 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin
(100 μg/ml). Cells were cultured at 37 °C in a 5% CO2 water-
saturated atmosphere to subconﬂuence and starved for 24 h in a
serum-free medium. Thereafter they were cultured for a further 6,
24 or 48 h in a serum-free medium in the presence of 20 ng/mlTGF-β1 (BD Bioscience), or 100 μg/ml BSA (Sigma), or 100 μg/ml of
glycated albumin (AGE) (obtained as described [19]), or 10 ng/ml FGF-2
(BD Bioscience) or 50 μg/ml low molecular weight heparin (LMWH).
2.2. Gene expression analysis
Total RNA was extracted from the cell monolayer using the “Trizol”
reagent (Invitrogen), in compliance with the manufacturer's instruc-
tions. Yield and purity were checked using the Nanodrop (EuroClone)
and total RNA from each sample was reverse transcribed into cDNA
using SuperScript II Reverse Transcriptase (Invitrogen). Real-time PCR
was performed on an ABI-Prism 7500 using Power SYBR Green Master
Mix 2X (Applied Biosystems). To quantify gene expression the compar-
ative Ct method (ΔΔ Ct) was used and the relative quantiﬁcation (RQ)
was calculated as 2−ΔΔCt. The presence of non-speciﬁc ampliﬁcation
products was excluded by melting curve analysis. A quantitative analy-
sis was performed to evaluate expression of α-SMA, FN, VIM, MMP-9,
and HPSE and normalized to GAPDH. The forward and reverse primer
sequences were: α-SMA: f-GAAGAAGAGGACAGCACTG, r-TCCCATTCCC
ACCATCAC; FN: f-GTGTGTTGGGAATGGTCGTG, r-GACGCTTGTGGAAT
GTGTCG; VIM: f-AAAACACCCTGCAATCTTTCAGA, r-CACTTTGCGTTCAA
GGTCAAGAC; MMP-9: f-CCTGGAGACCTGAGAACCAATC, r-CCACCCGA
GTGTAACCATAGC; HPSE: f-ATTTGAATGGACGGACTGC, r-GTTTCTCCTA
ACCAGACCTTC; TGF-β1: f-CGTGGAGCTGTACCAGAAAT, r- GATAACCA
CTCTGGCGAGTC; GAPDH: f- ACACCCACTCCTCCACCTTT, r-TCCACCAC
CCTGTTGCTGTA; HPSE: f-ATTTGAATGGACGGACTGC r—GTTTCTCCTAA
CCAGACCTTC [19].
2.3. Immunoﬂuorescence for α-SMA, VIM and FN.
Wt and HPSE-silenced cells were seeded in 22-mm glass dishes and
cultured to subconﬂuence, serum-starved for 24 h, and then incubated
with or without the different treatments for 48 h to analyze α-SMA,
VIM and FN protein expression. Cells were ﬁxed in 4% paraformalde-
hyde and permeabilized in PBS+ 0.2% Triton-X100. Cells were incubat-
ed with primary antibodies for α-SMA (mouse anti-α-smooth muscle
actin, 1A4, Sigma), VIM (Monoclonal Mouse Anti-Vimentin, Clone V9,
Dako) and FN (Anti-Fibronectin antibody [IST-9] ab6328, Abcam) over-
night at 4 °C in PBS with 1% BSA, then washed three times for 5 min/
each with PBS before incubating them for 1 h at 37 °C with the second-
ary antibody (goat anti-mouse IgG-FITC; Millipore) in PBS with 1% BSA.
Nuclei were counterstainedwith Hoechst 33258. Images were acquired
by confocal microscope LeicaSP5.
2.4. Zymography
MMPs activity in cells conditioned media was assessed by gelatin
substrate zymography. Conditionedmediawere prepared by incubating
subconﬂuent cells in a serum-free medium for 24 h, then with or with-
out 20 ng/ml TGF-β1 for a further 24, 48 or 72 h. Zymography was car-
ried out using standard procedure [25]. Equal amounts of conditioned
media were resolved in a non-reducing sample buffer on 10% SDS-
PAGE gels copolymerized with 0.1% gelatin. After electrophoresis, the
gels were washed twice for 30 min/each in 2.5% Triton X-100 at room
temperature to remove SDS, then equilibrated for 30min in collagenase
buffer (50 mM Tris, 200 mMNaCl, 5 mM CaCl2 and 0.02% Triton X-100,
pH 7.4), and ﬁnally incubated overnightwith fresh collagenase buffer at
37 °C. After incubation, gels were stained in 0.1% Comassie Brilliant Blue
R-250 30% MetOH/10% acetic acid for 1 h and destained in 30% MetOH/
10% acetic acid. Digestion bands were analyzed using ImageJ software
(http://rsb.info.nih.gov/ij/).
2.5. TGF-β1 ELISA assay
The release of TGF-β1 in the conditioned media of wt and HPSE-
silenced tubular cells was measured by an ELISA (RAB0460, Sigma-
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conditionedmedium of wt and HPSE-silenced cells treated or untreated
with 20 ng/ml TGF-β1, or 100 μg/ml BSA, or 100 μg/ml of AGE, or
10 ng/ml FGF-2 was added to a well plate covered with an antibody
anti-TGF-β1. To the plate was also added serial dilution of TGF-β1 stan-
dards. The plate was then incubated overnight at 4 °Cwith gentle shak-
ing. Subsequently, the platewaswashed four timeswith 1×washbuffer
and then 100 μl of 1× biotinilated antibody was added to each well and
incubated at room temperature for 1 h. After four washes, 100 μl of TMB
One-Step Substrate Reagent was added to each well and kept 30 min at
room temperature in the dark. The colorimetric reaction was stopped
with 100 μl of Stop Solution. Absorbance was immediately read at
450 nm. The TGF-β1 amount in each sample was calculated by plotting
its O.D. value on the TGF-β1 standard curve. Each sample was tested in
triplicate.Fig. 2. TGF-β release in the medium. An ELISA assay was used to quantify the release of
TGF-β1 in the conditioned media of wt and HPSE-silenced tubular cells treated for 48 h
with BSA, AGE, and FGF-2. The results represent the mean ± SD of two independent ex-
periments performed in triplicate (*p b 0.05, **p b 0.001 vs wt untreated).2.6. Statistics
Standard deviations and means of the real-time PCR data were cal-
culated with Rest2009 software. Differences between wt and HPSE-
silenced cells, or between treated and untreated cells, were compared
using Student's test. A p value≤0.05 was set as the level of signiﬁcance
for all tests.3. Results
3.1. Role of HPSE on TGF-β induction by pro-ﬁbrotic factors
Several pieces of evidence highlight the fact that heparanase can
control the development of EMT in tubular cells and thus regulate the
progression of ﬁbrosis [20,24]. HPSE resulted up-regulated in tubular
epithelial cells in response to several pro-ﬁbrotic factors (albumin
(BSA) and glycated albumin (AGE) and FGF-2) which are typically in-
creased at the onset of DN [19,20]. Moreover, Jil N. et al. provided evi-
dence that the lack of HPSE may regulate the expression of TGF-β in
the setting of diabetic nephropathy [24].
Since TGF-β has a central role in the pathology of proximal tubular
cells we investigatedwhether HPSE is involved in TGF-β overexpression
in response to pro-ﬁbrotic factors. We treated wt and HPSE-silenced
cells with BSA, AGE and FGF-2 and then we analyzed TGF-β expression
at 6, 24 and48h. The 6 h treatmentwith albumin, AGE and FGF-2 result-
ed in a signiﬁcant increase of TGF-β gene expression inwt cells. InHPSE-
silenced tubular cells the treatment with albumin, AGE and FGF-2 did
not increase TGF-β expression even at longer times (Fig. 1).Fig. 1. Relative expression of TGF-β. Gene expression levels of TGF-β normalized to GAPDHwere
Gene expression levels were referred to un-treated wt and HPSE-silenced cells set equal to one
licate (**p b 0.001 vs wt untreated).Similarly, the pro-ﬁbrotic factors albumin, AGE and FGF-2 induced
the release of TGF-β in the conditionedmedium (48 h serum freemedi-
um) only in wt tubular cells (Fig. 2).
Since the results showed that the lack of HPSE prevents the increase
of TGF-β expression and secretion, and because HPSE can represent a
pharmacological target, the effect of the HPSE-inhibition by LMWH
was investigated. Wt tubular cells were treated with BSA, AGE and
FGF-2 with or without LMWH and TGF-β expression was assessed.
Gene expression analysis showed that LMWH did not inﬂuence basal
TGF-β but completely prevented its up-regulation induced by pro-
ﬁbrotic factors (Fig. 3).3.2. Effects of TGF-β on mesenchymal-associated markers
At the onset of renal ﬁbrosis, tubular cells are not the only source of
TGF-β as it can also be produced by endothelial and immune cells [3].
Since HPSE is able to regulate the EMT of tubular cells induced by FGF-
2 [20] we investigated whether HPSE modulates tubular cell response
to exogenous TGF-β.
Following 6, 24 and 48 h incubation of wt andHPSE-silenced tubular
cells with TGF-β, the gene expression of EMT associated markers (α-
SMA, VIM, FN and MMP9) was evaluated.
In wt cells TGF-β induced an early up-regulation of all the above
genes from the 6-h point, while the effect in HPSE silenced cells was
later, starting from the 24th hour or even later for VIM (Fig. 4A, B, C, D).assessed inwt andHPSE-silenced cells treated for 6, 24 and 48hwith BSA, AGE and FGF-2.
. The results represent themean± SD of two independent experiments performed in trip-
Fig. 3. TGF-β expression in LMWH-treated cells. Gene expression level of TGF-β normal-
ized to GAPDH was assessed in wt cells treated for 6 h with BSA, AGE and FGF-2 in the
presence or not of LMWH. Gene expression levels were referred to un-treated wt cells
set equal to one. The results represent the mean ± SD of two independent experiments
performed in triplicate (**p b 0.001 vs wt untreated).
Fig. 4. Relative expression of α-SMA, VIM, FN and MMP9. Gene expression levels of α-SMA (A)
HPSE-silenced cells treated for 6, 24 and 48 hwith TGF-β.α-SMA, VIM, FN andMMP9 gene expr
gene expression levels were referred to un-treated wt cells set equal to one. The results represe
b 0.001 vs wt untreated).
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cells, also sustains its autocrine loop by up-regulating HPSE. Thus, we
analyzed whether TGF-β regulates HPSE expression in tubular cells. As
expected, and previously reported, HPSE-silenced cells displayed a sig-
niﬁcant HPSE reduction [19]. Gene expression analysis showed that
both in wt and HPSE-silenced cells TGF-β did not modify HPSE expres-
sion levels (Fig. 4E).
Moreover, after 48 h of incubation of wt and HPSE-silenced tubular
cells with TGF-β, protein amount of EMT associated markers (α-SMA,
FN and VIM) was evaluated by immunoﬂuorescence. Results showed
that all three markers (α-SMA, FN and VIM) were clearly up-regulated
both in wt and HPSE-silenced cells treated with TGF-β (Fig. 5).
The evaluation of MMP activity in serum free conditioned media of
wt and HPSE-silenced cells treated with TGF-β for 24,48 and 72 h re-
vealed that, in wt tubular cells, TGF-β increases the release of active
MMP9 progressively, from 24 to 72 h. At 72 h, TGF-β induced a four-
fold increase of active MMP9 in comparison with wt untreated cells. In
HPSE-silenced cells, TGF-β increased the release of active MMP9 after
48 and 72 h of treatment but not at 24 h. (Fig. 6)., VIM (B), FN (C) MMP9 (D) and HPSE (E) normalized to GAPDHwere assessed in wt and
ession levelswere referred to un-treatedwt andHPSE-silenced cells set equal to one. HPSE
nt themean ± SD of two independent experiments performed in triplicate (*p b 0.05, **p
Fig. 5. α-SMA, VIM and FN protein expression after TGF-β treatment. Representative im-
ages of one of two immunostaining experiments for α-SMA, VIM and FN in wt and
HPSE-silenced cells, treated for 48 h with or without TGF-β.
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TGF-β produces an autocrine loop to sustain its signal (andEMT) [3];
thus we hypothesized that the delayed response of HPSE-silenced cells
to TGF-β could be due to alterations in this feedback.We analyzed TGF-
β gene expression inwt andHPSE-silenced cells treatedwith TGF-β. The
treatment induced a rapid signiﬁcant increase of the TGF-β gene expres-
sion in wt HK2 cells and this up-regulation lasted over time. In HPSE-
silenced cells TGF-β basal gene expression level was comparable to wt
cells, and incubation with TGF-β induced only a delayed and transient
overexpression of the TGF-β gene (Fig. 7).
4. Discussion
The shrunken kidney is the end stage ofmany kidney diseases. The ir-
reversible loss of kidney function prevents the body from eliminating
much of the waste and therefore involves the need for dialysis or organ
transplantation. Among the causes of chronic renal failure, diabetic ne-
phropathy is one of the most common in developed countries [3]. The
damage to the renal tissues caused by diabetes is due to the high concen-
tration of glucose, the products of advanced glycation and proteinuria.
Regardless of etiology, the main mechanism responsible for chronic
renal failure is tubulo-interstitial ﬁbrosis, which is the process of pro-
gressive scarring of the interstitial space caused by myoﬁbroblasts.
These α-SMA positive cells secrete large amounts of extracellular ma-
trix and have contractile properties [1]. Given the incidence of chronic
kidney diseases potentially at risk of ESRD and the lack of effective ther-
apeutic methods able to prevent it, studies aimed at understanding the
molecular and biological basis of tubulo-interstitial ﬁbrosis are of prime
importance.
A mechanism which appears to contribute to the increase of
myoﬁbroblasts in the interstitium during renal ﬁbrosis is the epithelial–
mesenchymal transition of proximal tubular cells [5]. These cells lose
their identity as epithelial cells and differentiate into myoﬁbroblasts.
Among the pro-ﬁbrotic stimuli that activate the ﬁbroblasts into
myoﬁbroblasts, FGF-2 and TGF-β are main inducers of EMT of proximal
tubule epithelial cells [9,26]. Studies have revealed a role of the enzyme
HPSE in regulating the EMT induced by these pro-ﬁbrotic growth fac-
tors. Indeed, tubular epithelial cells silenced for HPSE, do not undergo
EMT induced by FGF-2 [20]. Furthermore, in the HPSE knock-out
mouse no increase of TGF-β occurs in the kidney when diabetic is in-
duced [24].
Given the cardinal role of TGF-β in triggering EMT and the associated
ﬁbrosis, the present study aimed at understanding whether HPSE is a
regulator element of this growth factor. In-vitro analysis shows that
the absence of HPSE prevents the increased synthesis of TGF-β by tubu-
lar cells in response to pro-ﬁbrotic stimuli such as FGF-2, AGE and BSA.
This ﬁnding is similar to the observation that in diabetic HPSE ko mice
renal TGF-β is not overexpressed [24]. Moreover, the lack of HPSE
does not prevent EMT induced by TGF-β although slowing the onset.
As a consequence of these two effects, a major global role of HPSE
could be expected in the regulation of EMT by TGF-β.
Hyperglycemia, proteinuria, and AGEs are the mainmediators of tu-
bular damage and strong inducers of tubulo-interstitial ﬁbrosis in dia-
betic nephropathy [27]. The in vivo exposure to AGE and to high
concentrations of glucose and albumin ﬁltered by the glomeruli induces
the over-production of TGF-β by proximal tubule cells. Even cytokines
and growth factors such as FGF-2, released by inﬂammatory cells, stim-
ulate an increased expression of TGF-β in the tubular cells.
The capacity of these stimuli to increase the production of TGF-βwas
conﬁrmed in wt tubular cells. In cells lacking HPSE, however, BSA, AGE
and FGF-2 did not modify the expression of TGF-β. That it was the lack
of HPSE which prevented the increase in TGF-β overexpression is prov-
en by the treatmentwith lowmolecularweight heparin (anHPSE inhib-
itor) after which the over-expression of TGF-βwas prevented following
stimulation with BSA, AGE and FGF-2.
Fig. 6.MMP9activity. Above, a representative gelatin zymographydisplayingMMP9digestion bands produced by serum-freemediumofwt andHPSE-silencedHK2 cells cultured for 24, 48 and
72 h with TGF-β. Below, densitometric analysis of MMP9 digestion bands expressed as a percentage of untreated wt and HPSE-silence cells respectively. Results represent the mean ± SD of
three independent experiments performed in triplicate (*p b 0.05, **p b 0.001 vs wt untreated).
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bular epithelial cells in response to pro-ﬁbrotic stimuli. These data give
an explanation at the molecular level of the fact that the HPSE-ko-
mouse does overexpress TGF–β and possibly also of the fact that it
does not develop diabetic nephropathy [24].
At the onset of renal ﬁbrosis, TGF-β is produced by several cell types
such as endothelial and immune cells [3]. Since HPSE is able to regulate
the EMT of tubular cells induced by FGF-2 [20] we hypothesized that
HPSE could modulate tubular cell response to exogenous TGF-β.
The phenotypical change distinctive of EMT is characterized by the
increase in speciﬁc markers of mesenchymal cells such as VIM, α-SMA
and FN which is indeed expressed in wt tubular cells when stimulated
with TGF-β after a few hours of treatment, suggesting a rapid response
of the cells to the stimulus. These data conﬁrm that TGF-β is a potent in-
ducer of EMT. The expression of thesemarkers was also increased in the
absence of HPSE, but not as rapidly as inwt cells suggesting that the lack
of HPSE may, in some way, hinder the activity of TGF-β and interfere
with the activation or operation of its signaling pathway.Fig. 7. Relative expression of TGF-β quantiﬁed by real-time PCR and normalized to
GAPDH. Gene expression levels of TGF-β normalized to GAPDH were assessed in wt and
HPSE-silenced cells treated for 6, 24 and 48 hwith TGF-β. Gene expression levelswere re-
ferred to un-treatedwt and HPSE-silenced cells set equal to one. The results represent the
mean ± SD of two independent experiments performed in triplicate (**p b 0.001 vs wt
untreated).During tubulo-interstitial ﬁbrosis, TGF-β induces an autocrine loop
that ampliﬁes the effects of this growth factor. [26]. Present results con-
ﬁrm that this autocrine loop is activated in wt tubular cells stimulated
with TGF-β. Similarly to the induction of mesenchymal markers of
EMT, the lack of HPSE in tubular cells did not prevent the TGF-β from ac-
tivating its transcription but caused a delay. Again this suggests that
HPSE can support the TGF-β in rapidly activating the transcription of
its target genes. Moreover, the duration of activation of the loop seems
to be inﬂuenced by HPSE. In the presence of HPSE, in fact, the expression
of TGF-βwasmaintained signiﬁcantly elevated over timewhile in its ab-
sence it quickly returned to baseline values. This decreasing trend that
occurs in silenced cells was not observed for the mesenchymal markers.
One possible explanation is the fact that over-expression of mesenchy-
mal markers is also supported by several transcription factors whose ex-
pression is activated by TGF-β itself [28].
Another well-known effect of TGF-β is the induction of MMPs, par-
ticularly MMP-9, by the epithelial cells. The activity of MMP-9 involves
the degradation of the tubular basement membrane thus facilitating
cell migration [5]. MMPs also activate the latent form of TGF-β anchored
to the matrix, one more example by which TGF-β sustains its signaling
pathway [29].
In accordance with the foregoing considerations, the tubular cells
treated with TGF-β increased the expression, release and activity of
MMP-9. The trend of gene expression and extracellular activity of
MMP-9 are comparable. In fact, during TGF-β treatment, wt tubular
cells expressed a high amount of MMP-9 which remained high over
time. MMP-9 was secreted and its progressive accumulation in the cul-
ture mediumwas demonstrated by zymographyc analysis. The analysis
of the MMP activity reconﬁrmed that HPSE-silenced cells release less
MMP-9 compared with wt tubular cells [20]. However, the lack of
HPSE did not prevent the TGF-β-induced increase ofMMP-9 expression.
Indeed, the expression levels of MMP-9 in HPSE-silenced cells reached
levels comparable to those of wt cells but such an increase was delayed.
Considering that MMP-9 is a target gene of TGF-β, this result supports
the hypothesis that HPSE facilitates the TGF-β in rapidly exerting its bi-
ological activities.
The morphological and phenotypical changes of EMT induced by
TGF-β involve the loss of cell–cell junctional complexes and reorganiza-
tion of actin ﬁbers in stressﬁbers ensures that the tubular epithelial cells
2128 V. Masola et al. / Biochimica et Biophysica Acta 1843 (2014) 2122–2128acquire a mesenchymal phenotype and an increase in themigratory ca-
pacity of tubular cells which, thanks to the degradation of the tubular
basement membrane mediated by MMP-9, can move into the intersti-
tium [30].
Several hypotheses, which have to be conﬁrmed with future exper-
iments, may explain the different response of thewt and HPSE-silenced
cells to TGF-β: 1) In cells silenced for HPSE, heparan sulfate turnover is
compromised and the expression of syndecan-1, a cell surface proteo-
glycan, is increased [19]. The increased amount of heparan sulfate ex-
posed on the cell surface could sequester TGF-β and delay and/or
modulate its interaction with receptors. 2) TGF-β induces EMT in tubu-
lar cells through the activation of SMAD-dependent and some SMAD-
independent pathways [31]. Previous studies [19] have shown that
the lack of HPSE in tubular epithelial cells involves an abnormal activa-
tion of the PI3K/Akt patyhway in response to FGF-2. This suggests that
even one of the TGF-β signaling pathwaysmay be altered in the absence
of HPSE. 3) The absence of HPSE may inﬂuence the expression of the
proteoglycan β-glycan that acts as a co-receptor of the TGF-β. This hy-
pothesis is based on the fact that the expression of another membrane
heparan-sulphate proteoglycan, syndecan-1, is regulated by HPSE both
in tubular cells and in other cell models [32].
5. Conclusions
Overall, these data conﬁrm that heparanase is an important player in
renal ﬁbrosis: A) HPSEmodulates TGF-β induced EMT, in particular, the
lack of HPSE delays tubular cell transdifferentiation and impairs the
TGF-β autocrine loop and B) HPSE is needed for the pathological TGF-
β overexpression in response to pro-ﬁbrotic factors such as overload
of albumin, AGE and FGF-2.
Given the incidence of chronic renal failure and the need for effective
treatments, these ﬁndings put HPSE forward as a potential and impor-
tant drug target in the treatment of kidney disease and renal ﬁbrosis.
The understanding of the molecular mechanisms by which HPSE
controls the EMT in renal tubular cells is therefore of fundamental
importance.
Altogether, these data conﬁrm that strategies aimed at inhibiting
heparanase could be a useful tool in controlling several mechanisms
leading to organ ﬁbrosis.
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